5-azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity

Mediators of Inflammation

Volumn 2014, Issue , 2014, Pages

  Stübig, Thomas ^a   Badbaran, Anita ^a   Luetkens, Tim ^a   Hildebrandt, York ^a   Atanackovic, Djordje ^a   Binder, Thomas M C ^a   Fehse, Boris ^a   Kröger, Nicolaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; GAMMA INTERFERON; INTERLEUKIN 10; PROTEIN P15; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; TRANSFORMING GROWTH FACTOR BETA; ANTINEOPLASTIC ANTIMETABOLITE; LACTATE DEHYDROGENASE;

ADAPTIVE IMMUNITY; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY DEVICE; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CELL GROWTH; CELL STRAIN HL 60; CELL STRAIN K 562; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG WITHDRAWAL; EFFECTOR CELL; FLOW CYTOMETRY; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; LEUKEMIA RELAPSE; LYMPHOCYTE COUNT; MALE; MEMORY T LYMPHOCYTE; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TUMOR CELL DESTRUCTION; TUMOR IMMUNITY; ALLOTRANSPLANTATION; CELL LINEAGE; CYTOLOGY; HL 60 CELL LINE; INFLAMMATION; K562 CELL LINE; METABOLISM; MIDDLE AGED; PHENOTYPE; STEM CELL TRANSPLANTATION;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CD8-POSITIVE T-LYMPHOCYTES; CELL LINEAGE; HL-60 CELLS; HUMANS; INFLAMMATION; K562 CELLS; L-LACTATE DEHYDROGENASE; LEUKEMIA; MALE; MIDDLE AGED; PHENOTYPE; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84897487192     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2014/418292     Document Type: Article

References (43)

1. Delcuve G. P., Rastegar M., Davie J. R., Epigenetic control. Journal of Cellular Physiology 2009 219 2 243 250 10.1002/jcp.21678
2. Esteller M., Cancer epigenomics: DNA methylomes and histone-modification maps. Nature Reviews Genetics 2007 8 4 286 298 10.1038/nrg2005 (Pubitemid 46439286)
3. Silverman L. R., Demakos E. P., Peterson B. L., Kornblith A. B., Holland J. C., Odchimar-Reissig R., Stone R. M., Nelson D., Powell B. L., DeCastro C. M., Ellerton J., Larson R. A., Schiffer C. A., Holland J. F., Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. Journal of Clinical Oncology 2002 20 10 2429 2440 2-s2.0-0037093195 10.1200/JCO.2002.04.117 (Pubitemid 34525728)
4. Fenaux P., Mufti G. J., Hellstrom-Lindberg E., Santini V., Gattermann N., Germing U., Sanz G., List A. F., Gore S., Seymour J. F., Dombret H., Backstrom J., Zimmerman L., McKenzie D., Beach C. L., Silverman L. R., Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. Journal of Clinical Oncology 2010 28 4 562 569 2-s2.0-77449149373 10.1200/JCO.2009.23.8329
5. Stresemann C., Lyko F., Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. International Journal of Cancer 2008 123 1 8 13 2-s2.0-43949136445 10.1002/ijc.23607 (Pubitemid 351705186)
6. Almstedt M., Blagitko-Dorfs N., Duque-Afonso J., Karbach J., Pfeifer D., Jäger E., Lübbert M., The DNA demethylating agent 5-aza-2′- deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. Leukemia Research 2010 34 7 899 905 2-s2.0-77952952304 10.1016/j.leukres.2010.02.004
7. Atanackovic D., Luetkens T., Kloth B., Fuchs G., Cao Y., Hildebrandt Y., Meyer S., Bartels K., Reinhard H., Lajmi N., Hegewisch-Becker S., Schilling G., Platzbecker U., Kobbe G., Schroeder T., Bokemeyer C., Kröger N., Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia. American Journal of Hematology 2011 86 11 918 922 2-s2.0-80054043545 10.1002/ajh.22141
8. + T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 2010 116 11 1908 1918 2-s2.0-77956924038 10.1182/blood-2009-11-249474
9. Lubbert M., Bertz H., Wasch R., Marks R., Ruter B., Claus R., Finke J., Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting. Bone Marrow Transplantation 2010 45 4 627 632 2-s2.0-77950614210 10.1038/bmt.2009.222
10. Czibere A., Bruns I., Kroger N., Platzbecker U., Lind J., Zohren F., Fenk R., Germing U., Schröder T., Gräf T., Haas R., Kobbe G., 5-azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis. Bone Marrow Transplantation 2010 45 5 872 876 2-s2.0-77952419308 10.1038/bmt.2009.266
11. Schroeder T., Czibere A., Platzbecker U., Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia 2013 27 6 1229 1235 10.1038/leu.2013.7
12. de Lima M., Giralt S., Thall P. F., de Padua Silva L., Jones R. B., Komanduri K., Braun T. M., Nguyen H. Q., Champlin R., Garcia-Manero G., Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 2010 116 23 5420 5431 2-s2.0-78649601394 10.1002/cncr.25500
13. Sanchez-Abarca L. I., Gutierrez-Cosio S., Santamaria C., Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. Blood 2010 115 1 107 121 10.1182/blood-2009-03-210393
14. Wilson C. B., Rowell E., Sekimata M., Epigenetic control of T-helper-cell differentiation. Nature Reviews Immunology 2009 9 2 91 105 10.1038/nri2487
15. + regulatory T cells. Nature Immunology 2003 4 4 330 336 2-s2.0-0037385330 10.1038/ni904 (Pubitemid 36432314)
16. Polansky J. K., Kretschmer K., Freyer J., Floess S., Garbe A., Baron U., Olek S., Hamann A., von Boehmer H., Huehn J., DNA methylation controls Foxp3 gene expression. European Journal of Immunology 2008 38 6 1654 1663 2-s2.0-49649107703 10.1002/eji.200838105
17. Lal G., Zhang N., van der Touw W., Ding Y., Ju W., Bottinger E. P., Reid S. P., Levy D. E., Bromberg J. S., Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. The Journal of Immunology 2009 182 1 259 273 2-s2.0-59849085588
18. Chappell C., Beard C., Altman J., Jaenisch R., Jacob J., DNA methylation by DNA methyltransferase 1 is critical for effector CD8 T cell expansion. The Journal of Immunology 2006 176 8 4562 4572 2-s2.0-33645770934
19. Kersh E. N., Fitzpatrick D. R., Murali-Krishna K., Shires J., Speck S. H., Boss J. M., Ahmed R., Rapid demethylation of the IFN- γ gene occurs in memory but not naive CD8 T cells. The Journal of Immunology 2006 176 7 4083 4093 2-s2.0-33646058925 (Pubitemid 44264387)
20. Schoenborn J. R., Dorschner M. O., Sekimata M., Santer D. M., Shnyreva M., Fitzpatrick D. R., Stamatoyonnapoulos J. A., Wilson C. B., Comprehensive epigenetic profiling identifies multiple distal regulatory elements directing transcription of the gene encoding interferon- γ Nature Immunology 2007 8 7 732 742 2-s2.0-34250773899 10.1038/ni1474 (Pubitemid 46965349)
21. Schmelz K., Wagner M., Dorken B., Tamm I., 5-aza-2′-deoxycytidine induces p21 WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia. International Journal of Cancer 2005 114 5 683 695 2-s2.0-14844313747 10.1002/ijc.20797 (Pubitemid 40344429)
22. + antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions. Blood 2006 108 6 2106 2113 2-s2.0-33746908248 10.1182/blood-2006-03-007427 (Pubitemid 44395027)
23. Liu Z., Kim J. H., Falo L. D. Jr., You Z., Tumor regulatory T cells potently abrogate antitumor immunity. The Journal of Immunology 2009 182 10 6160 6167 2-s2.0-77952391928 10.4049/jimmunol.0802664
24. Sercan O., Stoycheva D., Hammerling G. J., Arnold B., Schuler T., IFN- γ receptor signaling regulates memory CD 8 + T cell differentiation. The Journal of Immunology 2010 184 6 2855 2862 10.4049/jimmunol.0902708
25. Ophir E., Eidelstein Y., Afik R., Bachar-Lustig E., Reisner Y., Induction of tolerance to bone marrow allografts by donor-derived host nonreactive ex vivo -induced central memory CD8 T cells. Blood 2010 115 10 2095 2104 2-s2.0-77950424584 10.1182/blood-2009-10-248716
26. Araki K., Turner A. P., Shaffer V. O., Gangappa S., Keller S. A., Bachmann M. F., Larsen C. P., Ahmed R., mTOR regulates memory CD8 T-cell differentiation. Nature 2009 460 7251 108 112 2-s2.0-67650074206 10.1038/nature08155
27. Schroeder T., Frobel J., Cadeddu R. P., Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation. Leukemia 2013 27 9 1910 1913 10.1038/leu.2013.64
28. Merlo A., Herman J. G., Mao L., Lee D. J., Gabrielson E., Burger P. C., Baylin S. B., Sidransky D., 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nature Medicine 1995 1 7 686 692 2-s2.0-0029011539 10.1038/nm0795-686
29. Gonzalez-Zulueta M., Bender C. M., Yang A. S., Nguyen T., Beart R. W., van Tornout J. M., Jones P. A., Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Research 1995 55 20 4531 4535 2-s2.0-0028875205
30. Hannon G. J., Beach D., p 15 INK4B is a potential effector of TGF- β -induced cell cycle arrest. Nature 1994 371 6494 257 261 2-s2.0-0028168242 10.1038/371257a0
31. Goodyear O. C., Dennis M., Jilani N. Y., Loke J., Siddique S., Ryan G., Nunnick J., Khanum R., Raghavan M., Cook M., Snowden J. A., Griffiths M., Russell N., Yin J., Crawley C., Cook G., Vyas P., Moss P., Malladi R., Craddock C. F., Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood 2012 119 14 3361 3369 2-s2.0-84859582203 10.1182/blood-2011-09-377044
32. + regulatory T cells. The Journal of Immunology 2006 177 2 896 904 2-s2.0-33745820353 (Pubitemid 44036590)
33. - T cells by an IL-10-dependent mechanism. The Journal of Allergy and Clinical Immunology 2004 114 2 296 301 2-s2.0-4344696812 10.1016/j.jaci.2004.04.048 (Pubitemid 39119027)
34. Szalmas A., Banati F., Koroknai A., Lineage-specific silencing of human IL-10 gene expression by promoter methylation in cervical cancer cells. European Journal of Cancer 2008 44 7 1030 1038 10.1016/j.ejca.2008.02.046
35. Zhou X., Bailey-Bucktrout S. L., Jeker L. T., Penaranda C., Martínez-Llordella M., Ashby M., Nakayama M., Rosenthal W., Bluestone J. A., Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nature Immunology 2009 10 9 1000 1007 2-s2.0-69049107358 10.1038/ni.1774
36. Fujio K., Okamura T., Yamamoto K., The family of IL-10-secreting CD4 + T cells. Advances in Immunology 2010 105 99 130 10.1016/S0065-2776(10)05004-2
37. Konya C., Goronzy J. J., Weyand C. M., Treating autoimmune disease by targeting CD8 + T suppressor cells. Expert Opinion on Biological Therapy 2009 9 8 951 965 2-s2.0-67650699325 10.1517/14712590903020759
38. Mayer C. T., Floess S., Baru A. M., Lahl K., Huehn J., Sparwasser T., CD8 + Foxp3 + T cells share developmental and phenotypic features with classical CD4 + Foxp3 + regulatory T cells but lack potent suppressive activity. European Journal of Immunology 2011 41 3 716 725 2-s2.0-79951804510 10.1002/eji.201040913
39. Jones B., Chen J., Inhibition of IFN- γ transcription by site-specific methylation during T helper cell development. The EMBO Journal 2006 25 11 2443 2452 10.1038/sj.emboj.7601148 (Pubitemid 44012227)
40. Kannanganat S., Ibegbu C., Chennareddi L., Robinson H. L., Amara R. R., Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells. Journal of Virology 2007 81 16 8468 8476 2-s2.0-34547773111 10.1128/JVI.00228-07 (Pubitemid 47242819)
41. Rudek M. A., Zhao M., He P., Hartke C., Gilbert J., Gore S. D., Carducci M. A., Baker S. D., Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. Journal of Clinical Oncology 2005 23 17 3906 3911 2-s2.0-21244447049 10.1200/JCO.2005.07.450 (Pubitemid 46218693)
42. Costantini B., Kordasti S. Y., Kulasekararaj A. G., The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome. Haematologica 2013 98 8 1196 1205 10.3324/haematol.2012.074823
43. Pages F., Berger A., Camus M., Sanchez-Cabo F., Costes A., Molidor R., Mlecnik B., Kirilovsky A., Nilsson M., Damotte D., Meatchi T., Bruneval P., Cugnenc P.-H., Trajanoski Z., Fridman W.-H., Galon J., Effector memory T cells, early metastasis, and survival in colorectal cancer. The New England Journal of Medicine 2005 353 25 2654 2666 2-s2.0-29144514645 10.1056/NEJMoa051424 (Pubitemid 41817714)